The short version
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Kygevvi
doxecitine and doxribtimine · DOXECITINE 2 g/1; DOXRIBTIMINE 2 g/1 · Powder, For Solution · Oral · UCB, Inc.
NDC 50474-0350-30 · 30 PACKET in 1 CARTON / 1 POWDER, FOR SOLUTION in 1 PACKET · NDA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Regulatory
- Application
- NDA219792
- TE code
- —
- Approval date
- Nov 3, 2025
- Patents / exclusivity
- 2 patents, 1 exclusivities
| Type | Number / code | Expires |
|---|---|---|
| exclusivity | NCE | Nov 3, 2030 |
| patent | 11649259 | Aug 19, 2040 |
| patent | 10471087 | Aug 7, 2036 |
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of doxecitine and doxribtimine (Powder, For Solution)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| UCB, Inc. | DOXECITINE 2 g/1; DOXRIBTIMINE 2 g/1 | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Kygevvi — NDC 50474-0350-30," retrieved September 3, 2026, https://drugdashboards.com/drug/50474035030.
Free to cite with attribution — see how the data is put together.